Schrodinger, Inc. (SDGR)
| Market Cap | 2.16B |
| Revenue (ttm) | 154.47M |
| Net Income (ttm) | -134.80M |
| Shares Out | 71.14M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,957,554 |
| Open | 29.75 |
| Previous Close | 29.45 |
| Day's Range | 29.04 - 30.74 |
| 52-Week Range | 20.71 - 79.75 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 65.66 (+115.9%) |
| Earnings Date | Aug 11, 2022 |
About SDGR
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. ... [Read more...]
Financial Performance
In 2021, Schrodinger's revenue was $137.93 million, an increase of 27.60% compared to the previous year's $108.10 million. Losses were -$100.39 million, 310.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price forecast is 65.66, which is an increase of 115.92% from the latest price.
News
Schrödinger Convenes Global Educators For Second Annual Educator's Day
NEW YORK--(BUSINESS WIRE)--Schrödinger convenes global educators for second annual Educator's Day.
Schrödinger to Present at Jefferies Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at the Jefferies Healthcare Conference.
Schrödinger Announces Appointment of Arun Oberoi to Board of Directors
NEW YORK--(BUSINESS WIRE)---- $SDGR--Schrödinger announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022.
Schrödinger to Present at Citi Biotech Virtual Co-Panel Day
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at Citi Biotech Virtual Co-Panel Day.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 12.73% and 36.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Schrödinger Reports First Quarter 2022 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported first quarter 2022 financial results.
Schrödinger to Announce First Quarter 2022 Financial Results on May 4
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported it will announce first quarter 2022 financial results on May 4.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported inducement grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association...
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported new preclinical data supporting advancement of its Wee1 Inhibitor Program at AACR 2022 Annual Meeting.
3 Hypergrowth Tech Stocks to Buy for Huge Upside Potential
These hypergrowth stocks are bargains after retreating for much of the last year. They will all perform very well for long-term investors.
Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present new preclinical data from its Wee1 Inhibitor Program at AACR Annual Meeting 2022.
Schrödinger to Present at Truist Securities Life Sciences AI Symposium - Biotech & Tools
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at Truist Securities Life Sciences AI Symposium - Biotech & Tools.
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -13.16% and 25.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported financial results for the fourth quarter and full year 2021.
Analysts Estimate Schrodinger, Inc. (SDGR) to Report a Decline in Earnings: What to Look Out for
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Schrödinger to Announce Fourth Quarter and Full-Year 2021 Financial Results on February 24
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will report Fourth Quarter and Full-Year 2021 Financial Results on February 24, 2022.
Schrödinger to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference.
Schrödinger Announces Acquisition of XTAL BioStructures, Inc.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the acquisition of XTAL BioStructures, Inc.
Schrödinger to Present at H.C. Wainwright BioConnect Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at the H.C. Wainwright BioConnect Conference.
Schrödinger Announces Retirement of Chief Financial Officer Joel Lebowitz
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the retirement of chief financial officer Joel Lebowitz.
3 Stocks That Can Make You Rich in Just a Few Years
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.
Schrödinger Reports Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program At American Society Of Hem...
NEW YORK--(BUSINESS WIRE)--Schrödinger reports preclinical data supporting advancement of its MALT1 Inhibitor Program at American Society of Hematology 2021 Annual Meeting.
Schrödinger to Participate in Five Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will participate in five upcoming investor conferences.
Schrödinger Awarded Grant to Accelerate Drug Discovery in Women's Health
NEW YORK--(BUSINESS WIRE)--Schrödinger today was awarded a grant to accelerate drug discovery in women's health.